CA-125 levels are predictive of survival in low-grade serous ovarian cancer—A multicenter analysis
dc.contributor.author | Wohlmuth, Christoph | |
dc.contributor.author | Djedovic, Vladimir | |
dc.contributor.author | Kjær, Susanne K. | |
dc.contributor.author | Jensen, Allan | |
dc.contributor.author | Glasspool, Rosalind | |
dc.contributor.author | Roxburgh, Patricia | |
dc.contributor.author | Defazio, Anna | |
dc.contributor.author | Johnatty, Sharon E. | |
dc.contributor.author | Webb, Penelope M. | |
dc.contributor.author | Modugno, Francesmary | |
dc.contributor.author | Lambrechts, Diether | |
dc.contributor.author | Schildkraut, Joellen M. | |
dc.contributor.author | Berchuck, Andrew | |
dc.contributor.author | Thomsen, Liv Cecilie Vestrheim | |
dc.contributor.author | Bjørge, Line | |
dc.contributor.author | Høgdall, Estrid | |
dc.contributor.author | Høgdall, Claus K. | |
dc.contributor.author | Goode, Ellen L. | |
dc.contributor.author | Winham, Stacey J. | |
dc.contributor.author | Matsuo, Keitaro | |
dc.contributor.author | Karlan, Beth Y. | |
dc.contributor.author | Lester, Jenny | |
dc.contributor.author | Goodman, Marc T. | |
dc.contributor.author | Thompson, Pamela J. | |
dc.contributor.author | Pejovic, Tanja | |
dc.contributor.author | Riggan, Marjorie J. | |
dc.contributor.author | Lajkosz, Katherine | |
dc.contributor.author | Tone, Alicia | |
dc.contributor.author | May, Taymaa | |
dc.date.accessioned | 2022-10-05T14:05:15Z | |
dc.date.available | 2022-10-05T14:05:15Z | |
dc.date.created | 2022-05-15T15:00:30Z | |
dc.date.issued | 2022-04-13 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://hdl.handle.net/11250/3024121 | |
dc.description.abstract | Objective: Studies on low-grade serous ovarian cancer (LGSC) are limited by a low number of cases. The aim of this study was to define the prognostic significance of age, stage, and CA-125 levels on survival in a multi-institutional cohort of women with pathologically confirmed LGSC. Methods: Women with LGSC were identified from the collaborative Ovarian Cancer Association Consortium (OCAC). Cases of newly diagnosed primary LGSC were included if peri-operative CA-125 levels were available. Age at diagnosis, FIGO stage, pre- and post-treatment CA-125 levels, residual disease, adjuvant chemotherapy, disease recurrence, and vital status were collected by the participating institutions. Progression-free (PFS) and overall survival (OS) were calculated. Multivariable (MVA) Cox proportional hazard models were used and hazard ratios (HR) calculated. Results: A total of 176 women with LGSC were included in this study; 82% had stage III/IV disease. The median PFS was 2.3 years and the median OS was 6.4 years. Age at diagnosis was not significantly associated with worse PFS (p = 0.23) or OS (p = 0.3) (HR per year: 0.99; 95%CI, 0.96–1.01 and 0.98; 95%CI 0.95–1.01). FIGO stage III/IV was independently associated with PFS (HR 4.26, 95%CI 1.43–12.73) and OS (HR 1.69, 95%CI 0.56–5.05). Elevated CA-125 (≥35 U/mL) at diagnosis was not significantly associated with worse PFS (p = 0.87) or OS (p = 0.78) in MVA. Elevated CA-125 (≥35 U/mL) after completion of primary treatment was independently associated with worse PFS (HR 2.81, 95%CI 1.36–5.81) and OS (HR 6.62, 95%CI 2.45–17.92). In the MVA, residual disease was independently associated with PFS (0.022), but not OS (0.85). Conclusion: Advanced LGSC was associated with poor long-term prognosis. FIGO stage and abnormal post-treatment CA-125 level are key prognostic factors inversely associated with PFS and OS. Highlights: 1. Through a multi-center collaborative effort, data from 176 women with low-grade serous ovarian cancer were analyzed. 2. Although low-grade serous ovarian cancer is often considered indolent, the progression-free and overall survival are poor. 3. Elevated post-treatment CA-125 levels are independently associated with poor survival. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | CA-125 levels are predictive of survival in low-grade serous ovarian cancer—A multicenter analysis | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 the authors | en_US |
dc.source.articlenumber | 1954 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/cancers14081954 | |
dc.identifier.cristin | 2024693 | |
dc.source.journal | Cancers | en_US |
dc.identifier.citation | Cancers. 2022, 14 (8), 1954. | en_US |
dc.source.volume | 14 | en_US |
dc.source.issue | 8 | en_US |
Tilhørende fil(er)
Denne innførselen finnes i følgende samling(er)
-
Department of Clinical Science [2294]
-
Registrations from Cristin [9489]